JP2022527796A5 - - Google Patents

Info

Publication number
JP2022527796A5
JP2022527796A5 JP2021558566A JP2021558566A JP2022527796A5 JP 2022527796 A5 JP2022527796 A5 JP 2022527796A5 JP 2021558566 A JP2021558566 A JP 2021558566A JP 2021558566 A JP2021558566 A JP 2021558566A JP 2022527796 A5 JP2022527796 A5 JP 2022527796A5
Authority
JP
Japan
Prior art keywords
pyridine
group
pharmaceutical composition
substituted
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021558566A
Other languages
English (en)
Japanese (ja)
Other versions
JP7284830B2 (ja
JP2022527796A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/053019 external-priority patent/WO2020201991A1/en
Publication of JP2022527796A publication Critical patent/JP2022527796A/ja
Publication of JP2022527796A5 publication Critical patent/JP2022527796A5/ja
Priority to JP2023049681A priority Critical patent/JP2023078421A/ja
Application granted granted Critical
Publication of JP7284830B2 publication Critical patent/JP7284830B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021558566A 2019-04-02 2020-03-30 タンパク質チロシンホスファターゼ阻害剤 Active JP7284830B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023049681A JP2023078421A (ja) 2019-04-02 2023-03-27 タンパク質チロシンホスファターゼ阻害剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962828356P 2019-04-02 2019-04-02
US62/828,356 2019-04-02
US202062992558P 2020-03-20 2020-03-20
US62/992,558 2020-03-20
PCT/IB2020/053019 WO2020201991A1 (en) 2019-04-02 2020-03-30 Protein tyrosine phosphatase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023049681A Division JP2023078421A (ja) 2019-04-02 2023-03-27 タンパク質チロシンホスファターゼ阻害剤

Publications (3)

Publication Number Publication Date
JP2022527796A JP2022527796A (ja) 2022-06-06
JP2022527796A5 true JP2022527796A5 (https=) 2022-09-02
JP7284830B2 JP7284830B2 (ja) 2023-05-31

Family

ID=70277430

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021558566A Active JP7284830B2 (ja) 2019-04-02 2020-03-30 タンパク質チロシンホスファターゼ阻害剤
JP2023049681A Pending JP2023078421A (ja) 2019-04-02 2023-03-27 タンパク質チロシンホスファターゼ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023049681A Pending JP2023078421A (ja) 2019-04-02 2023-03-27 タンパク質チロシンホスファターゼ阻害剤

Country Status (26)

Country Link
US (3) US11634417B2 (https=)
EP (1) EP3947367A1 (https=)
JP (2) JP7284830B2 (https=)
KR (1) KR102698608B1 (https=)
CN (1) CN113874363B (https=)
AU (1) AU2020251841B2 (https=)
BR (1) BR112021018664A2 (https=)
CA (1) CA3135555C (https=)
CL (2) CL2021002542A1 (https=)
CO (1) CO2021013030A2 (https=)
CR (1) CR20210501A (https=)
CU (1) CU20210080A7 (https=)
DO (1) DOP2021000206A (https=)
EC (1) ECSP21072994A (https=)
GE (2) GEP20237561B (https=)
IL (2) IL320682A (https=)
MA (1) MA55511A (https=)
MX (1) MX2021012122A (https=)
PE (1) PE20220141A1 (https=)
PH (1) PH12021552227A1 (https=)
PY (1) PY2018672A (https=)
SG (1) SG11202110502PA (https=)
TW (1) TWI766261B (https=)
UY (1) UY38628A (https=)
WO (1) WO2020201991A1 (https=)
ZA (1) ZA202108443B (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3860717A1 (en) 2018-10-03 2021-08-11 Gilead Sciences, Inc. Imidozopyrimidine derivatives
BR112021005733A2 (pt) 2018-10-17 2021-07-27 Array Biopharma Inc. inibidores de proteína tirosina fosfatase
CU20210080A7 (es) * 2019-04-02 2022-05-11 Array Biopharma Inc Triazinas sustituidas como inhibidores de proteína tirosina fosfatasa
IL299131A (en) 2020-06-18 2023-02-01 Revolution Medicines Inc Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
US20250195521A1 (en) 2020-09-03 2025-06-19 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
CA3194067A1 (en) 2020-09-15 2022-03-24 Revolution Medicines, Inc. Ras inhibitors
US20240025924A1 (en) * 2021-03-23 2024-01-25 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Heterocycle substituted ketone derivative, and composition and medicinal use thereof
TWI825637B (zh) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶-1,6(2h,7h)-二酮
WO2022206684A1 (zh) * 2021-03-31 2022-10-06 南京明德新药研发有限公司 一系列含Se的吡嗪类化合物及其应用
US20240190843A1 (en) * 2021-04-01 2024-06-13 Array Biopharma Inc. Crystalline form of a shp2 inhibitor
CN117460725A (zh) * 2021-04-01 2024-01-26 阵列生物制药公司 Shp2抑制剂的晶型
KR20240017811A (ko) 2021-05-05 2024-02-08 레볼루션 메디슨즈, 인크. 암의 치료를 위한 ras 억제제
TW202309052A (zh) 2021-05-05 2023-03-01 美商銳新醫藥公司 Ras抑制劑
JP2024516450A (ja) 2021-05-05 2024-04-15 レボリューション メディシンズ インコーポレイテッド 共有結合性ras阻害剤及びその使用
TW202244049A (zh) * 2021-05-12 2022-11-16 大陸商藥雅科技(上海)有限公司 Shp2磷酸酶抑制劑的製備及其應用
CN115960109B (zh) * 2021-05-31 2024-06-25 药雅科技(上海)有限公司 稠环类shp2磷酸酶抑制剂的制备及其应用
TW202319056A (zh) 2021-07-09 2023-05-16 南韓商治納輔醫藥科技有限公司 Shp2抑制劑及其用途
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
EP4417600A4 (en) * 2021-10-14 2025-02-19 Beijing Tide Pharmaceutical Co., Ltd. SHP2 INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF
JP2025510572A (ja) 2022-03-08 2025-04-15 レボリューション メディシンズ インコーポレイテッド 免疫不応性肺癌を治療するための方法
CN119095836A (zh) * 2022-03-23 2024-12-06 Array生物制药公司 Shp2抑制剂的结晶盐形式
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
CN115177622B (zh) * 2022-07-19 2024-09-17 中南大学湘雅二医院 多个化合物在制备治疗骨髓增殖性肿瘤的药物中的应用
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
CR20250420A (es) 2023-04-07 2025-11-20 Revolution Medicines Inc Inhibidores macrocíclicos de ras
AR132338A1 (es) 2023-04-07 2025-06-18 Revolution Medicines Inc Inhibidores de ras
CN121100123A (zh) 2023-04-14 2025-12-09 锐新医药公司 Ras抑制剂的结晶形式
CN121464140A (zh) 2023-04-14 2026-02-03 锐新医药公司 Ras抑制剂的结晶形式、含有其的组合物及其使用方法
WO2024218632A1 (en) 2023-04-17 2024-10-24 Array Biopharma Inc. Erk protein kinase inhibitors
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ras相關疾病或病症之組合療法
EP4735452A2 (en) 2023-06-30 2026-05-06 Merck Patent GmbH Heterobifunctional compounds for the degradation of kras protein
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ras抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US7834178B2 (en) 2006-03-01 2010-11-16 Bristol-Myers Squibb Company Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
AU2012323890A1 (en) 2011-10-14 2014-05-29 Array Biopharma Inc. Polymorphs of arry-380, a selective ErbB2 inhibitor and pharmaceutical compositions containing them
TW201408658A (zh) 2012-08-27 2014-03-01 Array Biopharma Inc 絲胺酸/酥胺酸激酶抑制劑
EP3053923B1 (en) 2013-09-30 2018-04-11 Korea Research Institute of Chemical Technology Triazolopyrazine derivatives as tyrosin kinase inhibitors
JO3517B1 (ar) * 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
ES2699351T3 (es) 2014-01-17 2019-02-08 Novartis Ag Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2
WO2015107494A1 (en) * 2014-01-17 2015-07-23 Novartis Ag 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
WO2016203405A1 (en) 2015-06-19 2016-12-22 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
US10287266B2 (en) * 2015-06-19 2019-05-14 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
EP3310779B1 (en) 2015-06-19 2019-05-08 Novartis AG Compounds and compositions for inhibiting the activity of shp2
WO2017210134A1 (en) 2016-05-31 2017-12-07 Board Of Regents, University Of Texas System Heterocyclic inhibitors of ptpn11
MX388576B (es) 2016-06-07 2025-03-20 Jacobio Pharmaceuticals Co Ltd Derivados heterociclicos novedosos utiles como inhibidores de shp2.
WO2017216706A1 (en) 2016-06-14 2017-12-21 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
EP4302834A3 (en) * 2016-07-12 2024-07-17 Revolution Medicines, Inc. 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
WO2018057884A1 (en) 2016-09-22 2018-03-29 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
TW202500565A (zh) 2016-10-24 2025-01-01 美商傳達治療有限公司 Shp2磷酸酶抑制劑及其使用方法
JP7240319B2 (ja) 2017-01-23 2023-03-15 レヴォリューション・メディスンズ,インコーポレイテッド アロステリックshp2阻害剤としての二環式化合物
KR20190110588A (ko) 2017-01-23 2019-09-30 레볼루션 메디슨즈, 인크. 알로스테릭 shp2 억제제로서의 피리딘 화합물
EA202190196A1 (ru) * 2017-03-23 2021-08-31 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
EP3630770B1 (en) 2017-05-26 2024-08-28 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
CA3074690A1 (en) 2017-09-07 2019-03-14 Revolution Medicines, Inc. Shp2 inhibitor compositions and methods for treating cancer
JP7447002B2 (ja) 2017-09-11 2024-03-11 クルーゾン・ファーマシューティカルズ・インコーポレイテッド SHP2のオクタヒドロシクロペンタ[c]ピロールのアロステリック阻害剤
EP3687997A1 (en) 2017-09-29 2020-08-05 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
TW201930292A (zh) 2017-10-12 2019-08-01 美商銳新醫藥公司 作為變構shp2抑制劑的吡啶、吡嗪和三嗪化合物
JP7361693B2 (ja) 2017-12-15 2023-10-16 レヴォリューション・メディスンズ,インコーポレイテッド アロステリックshp2阻害剤としての多環式化合物
WO2019152454A1 (en) 2018-01-30 2019-08-08 Research Development Foundation Shp2 inhibitors and methods of use thereof
AU2019240299B2 (en) 2018-03-21 2023-06-22 D.E. Shaw Research, Llc SHP2 phosphatase inhibitors and methods of use thereof
US12138263B2 (en) 2018-03-21 2024-11-12 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereof
RU2020133727A (ru) 2018-03-21 2022-04-21 Сучжоу Пухе Биофарма Ко., Лтд. Ингибиторы shp2 и их применение
CN112601750B (zh) 2018-08-10 2023-10-31 纳维尔制药有限公司 Ptpn11(shp2)抑制剂
US20210393623A1 (en) * 2018-09-26 2021-12-23 Jacobio Pharmaceuticals Co., Ltd. Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
BR112021005733A2 (pt) 2018-10-17 2021-07-27 Array Biopharma Inc. inibidores de proteína tirosina fosfatase
CU20210080A7 (es) * 2019-04-02 2022-05-11 Array Biopharma Inc Triazinas sustituidas como inhibidores de proteína tirosina fosfatasa

Similar Documents

Publication Publication Date Title
JP2022527796A5 (https=)
JP7079303B2 (ja) Retキナーゼ阻害剤としての置換ピラゾロ[1,5-a]ピリジン化合物
CN114599361B (zh) Prmt5抑制剂的药物组合物
US20230174519A1 (en) Inhibitors of Rho Associated Coiled-Coil Containing Protein Kinase
AU2007323644B2 (en) Compounds modulating c-fms and/or c-kit activity and uses therefor
CN105272930B (zh) 取代脲衍生物及其在药物中的应用
JP2024532733A (ja) 複素環式化合物及び使用方法
JP2023512113A5 (https=)
JP2022504936A5 (https=)
CN105294682A (zh) Cdk类小分子抑制剂的化合物及其用途
JP2001097889A (ja) Crfアンタゴニストおよび関連組成物の使用
IL163781A (en) Purine derivatives as kinase inhibitors
RU2015149937A (ru) Соединения для модулирования киназы и показания к их применению
RU2016111675A (ru) Соединения биарилацетамида и способы их применения
RU2017138100A (ru) Имидазолонилхинолины и их применение в качестве ингибиторов киназы атм
JP2018507214A5 (https=)
TW202140486A (zh) 經取代1,1'-聯苯基化合物及其使用方法
ME02635B (me) Novi derivati pirola, postupak njihove priprave i farmaceutski pripravci koji ih sadrže
AU2005215257A1 (en) Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
JP2020527174A5 (https=)
RU2013109776A (ru) Замещенные пиразолхиназолиновые производные в качестве ингибиторов киназы
RU2016105999A (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
CN102264368A (zh) 极光激酶抑制剂与抗cd20抗体的组合
EP2794605A1 (en) 2, 4-diamine-pyrimidine derivative as serine/threonine kinase inhibitors
JP2023529926A5 (https=)